E/C/F / tenofovir alafenamide was non-inferior to E/C/F / tenofovir disoproxil fumarate , with 800 ( 92 % ) of 866 patients in the tenofovir alafenamide group and 784 ( 90 % ) of 867 patients in the tenofovir disoproxil fumarate group having plasma HIV-1 RNA less than 50 copies per mL ( adjusted difference 20 % , 95 % CI -07 to 47 ) .